Profile
Martha Y.
Jimenez served as President, CEO, CFO, Secretary & Treasurer of Genova Biotherapeutics, Inc. in 2008.
She also served as President & Treasurer of Infrastructure Developments Corp.
from 2008 to 2009.
Former positions of Martha Y. Jimenez
| Companies | Position | End |
|---|---|---|
| INFRASTRUCTURE DEVELOPMENTS CORP. | President | 20/07/2009 |
Genova Biotherapeutics, Inc.
 Genova Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Genova Biotherapeutics, Inc. is a biotechnological drug development company with a focus on identifying, evaluating and acquiring new promising drugs for treatment and prevention of oncological and infectious diseases in human beings. The company currently holds rights to pending patent applications for three medicines. Patent applications for each of the three drugs are Prostate cancer treatment & Breast cancer treatment. Prostate cancer treatment relates to the use of short polypeptides for treatment of cancers and more particular for the treatment of prostate cancer. Breast cancer treatment provides treatment for patients suffering from cancer and more preferably from breast cancer using new lipid derivatives such as tetanolic acid. The company was founded in December 6, 2005 and is headquartered in New York, NY. | Director of Finance/CFO | 16/09/2008 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Infrastructure Developments Corp.
 Infrastructure Developments Corp. Engineering & ConstructionIndustrial Services Infrastructure Developments Corp. engages in engineering and construction services. It also offers project management services for construction projects. The company was founded on August 10, 2006 and is headquartered in Salt Lake City, UT. | Industrial Services |
Genova Biotherapeutics, Inc.
Genova Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Genova Biotherapeutics, Inc. is a biotechnological drug development company with a focus on identifying, evaluating and acquiring new promising drugs for treatment and prevention of oncological and infectious diseases in human beings. The company currently holds rights to pending patent applications for three medicines. Patent applications for each of the three drugs are Prostate cancer treatment & Breast cancer treatment. Prostate cancer treatment relates to the use of short polypeptides for treatment of cancers and more particular for the treatment of prostate cancer. Breast cancer treatment provides treatment for patients suffering from cancer and more preferably from breast cancer using new lipid derivatives such as tetanolic acid. The company was founded in December 6, 2005 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Martha Y. Jimenez
